The use of intravenous immune globulin in immunodeficiency diseases. N Engl J Med 1991; 325:110–17. , .
et al. Desensitization and subsequent kidney transplantation of patients using intravenous immunoglobulins (IVIg). Am J Transplant 2002; 2:758–60. , ,
et al. Intravenous immune globulin treatment inhibits crossmatch positivity and allows for successful transplantation of incompatible organs in living-donor and cadaver recipients. Transplantation 2003; 76:631–6. , ,
et al. Rituximab and intravenous immune globulin for desensitization during renal transplantation. N Engl J Med 2008; 359:242–51. , ,
et al. Beneficial effect of plasmapheresis and intravenous immunoglobulin on renal allograft survival of patients with acute humoral rejection. Transplantation 2003; 75:1490–5. , ,
Current approaches to treatment of antibody-mediated rejection. Pediatr Transplant 2005; 9:408–15. , , , , .
Fc gamma RIIB as a potential molecular target for intravenous gamma globulin therapy. J Allergy Clin Immunol 2001; 108:S95–8. , , .
IVIG and HLA antibodies. Evidence for inhibition of complement activation but not for anti-idiotypic activity. Am J Transplant 2005; 5:2786–90. , .
Modulation of mononuclear phagocyte function by intravenous gamma-globulin. J Immunol 1984; 132:745–50. , , , , .
Intravenous immunoglobulin mediates an increase in anti-platelet antibody clearance via the FcRn receptor. Thromb Haemost 2002; 88:898–9. , .
Reactivity of twenty-two cytotoxic human monoclonal HLA antibodies towards soluble HLA class I in an enzyme-linked immunosorbent assay (PRA-STAT). Hum Immunol 1997; 56:106–13. , , , , .
Effects of immunosuppressive drugs on purified human B cells: evidence supporting the use of MMF and rapamycin. Transplantation 2008; 86:1292–300. , , , , , .
Polyvalent immunoglobulin for intravenous use interferes with cell proliferation in vitro. J Clin Immunol 1992; 12:325–34. , , , .
Immune modulatory effects of immunoglobulins on cell-mediated immune responses in vitro. Scand J Immunol 1993; 38:477–84. , , , , .
et al. A-specific alloantibodies by high-dose intravenous immunoglobulins (IVIg). A potential tool for transplantation of immunized patients. Transplantation 1993; 56:335–7. , ,
Intravenous immunoglobulin suppression of HLA alloantibody in highly sensitized transplant candidates and transplantation with a histoincompatible organ. Transplantation 1994; 57:553–62. , , , , .
Cellular mechanisms in the in vitro inhibition of pokeweed mitogen-induced B cell differentiation by immunoglobulin for intravenous use. J Immunol 1986; 136:4407–13. .
Modulation of the immune response by immunoglobulin for intravenous use. I. Inhibition of pokeweed mitogen-induced B cell differentiation. Clin Exp Immunol 1985; 62:200–7. .
et al. Suppression of immunoglobulin production of lymphocytes by intravenous immunoglobulin. J Clin Immunol 1991; 11:152–8. , ,
The suppressive effect of gammaglobulin preparations on in vitro pokeweed mitogen-induced immunoglobulin production. Clin Exp Immunol 1986; 65:409–15. , , .
Contribution of stabilizing agents present in intravenous immunoglobulin preparations to modulation of mononuclear cell proliferation in vitro. Scand J Immunol 1996; 44:585–91. , , .
Intravenous immunoglobulins induce the in vitro differentiation of human B lymphocytes and the secretion of IgG. Blood 2003; 101:3065–73. , , , , .
The role of interleukin 2 in inducing Ig production in a pokeweed mitogen-stimulated mononuclear cell system. J Immunol 1987; 138:795–801. , , , , .
et al. Intravenous immunoglobulin inhibits IgE production in human B lymphocytes. J Allergy Clin Immunol 1998; 102:421–7. , ,
The effect of desensitization protocols on human splenic B-cell populations in vivo. Am J Transplant 2007; 7:402–7. , , , , , .
et al. Two novel assays of alloantibody-secreting cells demonstrating resistance to desensitization with IVIG and rATG. Am J Transplant 2008; 8:133–43. , ,
et al. Intravenous immunoglobulins suppress T-cell priming by modulating the bidirectional interaction between dendritic cells and natural killer cells. Blood 2007; 110:3253–62. , ,
Suppression of cytokine-dependent human T-cell proliferation by intravenous immunoglobulin. Clin Immunol Immunopathol 1994; 73:180–6. , , , , .
Antiidiotypes against autoantibodies in pooled normal human polyspecific Ig. J Immunol 1989; 143:4104–9. , .
Normal immunoglobulin G (IgG) for therapeutic use (intravenous Ig) contain antiidiotypic specificities against an immunodominant, disease-associated, cross-reactive idiotype of human anti-thyroglobulin autoantibodies. J Clin Invest 1990; 85:620–5. , .
et al. F(ab)′2-mediated neutralization of C3a and C5a anaphylatoxins: a novel effector function of immunoglobulins. Nat Med 2003; 9:431–8. , ,